Oral Isotretinoin in Melasma a Randomized Controlled Trial

Launched by ZAGAZIG UNIVERSITY · Dec 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of oral isotretinoin as a potential treatment for melasma, a skin condition that causes dark patches and can significantly affect people's self-esteem and quality of life. Melasma can be difficult to treat, and this study aims to see if a medication typically used for acne can help improve this condition. The trial is currently looking for participants between the ages of 18 and 50 who have been diagnosed with melasma. Women who can use two forms of birth control during the study are also welcome to participate.

If you join this study, you will be monitored closely to assess how well the medication works for your melasma. It's important to know that pregnant or nursing women, those currently on other melasma treatments, and individuals with certain health conditions may not be eligible to participate. This trial is a chance to contribute to research that could lead to better treatments for melasma, so if you are interested and meet the criteria, consider discussing it further with your doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age between 18 and 50 years
• • 2. Patients complaining of melasma.
• • 3. Patients with all types of melasma (epidermal, dermal and mixed)
• • 4. Sexually active women who is willing to follow at least 2 types of contraceptive methods during study period
• • 5. Patients with skin type I-V
• Exclusion Criteria:
• • 1. Pregnant or nursing women.
• • 2. Women on any concurrent therapy for melasma.
• • 3. Patients that are using any therapy for melasma for the last 45 days.
• • 4. Patient with abnormal liver function test or lipid profile.
• • 5. Patients with allergy or hypersensitivity to the assigned drugs.
• • 6. Women not willing to follow contraceptive methods at time of study.
• • 7. Patients on facial treatments or photosensitizing drugs within previous 6 months.
• • 8. Patients with back or joint pain.
• • 9. Patients with pre-existing or dormant dermatologic disease on the face that could interfere with the outcome of the study